<DOC>
	<DOCNO>NCT02267603</DOCNO>
	<brief_summary>This phase II trial study well pembrolizumab work treat patient Merkel cell cancer remove surgery control treatment , spread part body . Pembrolizumab may stimulate immune system identify destroy cancer cell .</brief_summary>
	<brief_title>Pembrolizumab Treating Patients With Advanced Merkel Cell Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine clinical efficacy MK-3475 ( pembrolizumab ) first systemic intervention patient advance Merkel cell carcinoma ( MCC ) . SECONDARY OBJECTIVES : I . To determine clinical activity MK-3475 first systemic intervention patient advance MCC . TERTIARY OBJECTIVES : I . To determine immune correlate clinical activity MK-3475 . OUTLINE : Patients receive pembrolizumab intravenously ( IV ) 30 minute day 1 . Treatment repeat every 21 day 24 month absence disease progression* unacceptable toxicity . * NOTE : Patients confirm disease progression may continue receive treatment otherwise clinically stable increase tumor burden 25 % follow initial confirmation progression . After completion study treatment , patient follow 30 day every 9-12 week 1 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Merkel Cell</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Patients must biopsyproven metastatic MCC locoregional MCC recur follow standard locoregional therapy surgery and/or radiation therapy Patients must measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 assess compute tomography ( CT ) scan , skin lesion measurable CT scan , measurement may perform caliper flexible ruler Note : stage IV evidence disease ( NED ) exclude criterion Have performance status = &lt; 1 Eastern Cooperative Oncology Group ( ECOG ) performance scale Life expectancy great 6 month Leukocytes &gt; = 2,000/mcL Absolute neutrophil count &gt; = 1,500/mcL Platelets &gt; = 100,000/mcL Hemoglobin &gt; = 9 g/dL OR &gt; = 5.6 mmol/L Serum total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) OR direct bilirubin = &lt; ULN patient total bilirubin level &gt; 1.5 x ULN Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 2.5 x institutional ULN OR = &lt; 5 x ULN patient liver metastasis Serum creatinine = &lt; 2.5 x ULN OR measure calculated* creatinine clearance ( CrCl ) ( glomerular filtration rate [ GFR ] also use place creatinine creatinine clearance [ CrCl ] ) &gt; = 30 mL/min subject creatinine level &gt; 2.5 x institutional ULN Creatinine clearance calculate per institutional standard Thyroid stimulate hormone ( TSH ) within institutional limit ( i.e . : normal ) ; TSH great less institutional limit patient may participate T4 within normal limit ( WNL ) ; patient may stable dose replacement thyroid medication ; dose adjustment allow needed Patients must provide tissue archival tumor sample newly obtain core , punch excisional biopsy tumor lesion deem relatively safe technically feasible Note : newly obtain biopsy preferable Female patient childbearing potential must negative urine serum pregnancy within 72 hour receive first dose study medication ; urine test positive confirm negative , serum pregnancy test require Note : woman childbearing potential must agree use 2 method birth control , surgically sterile , abstain heterosexual activity begin screen visit duration study participation , 120 day beyond last dose MK3475 administration ; patient childbearing potential surgically sterilize free menses &gt; 1 year ; woman become pregnant suspect pregnant partner participate study , inform treat physician immediately Men treat enrol protocol must agree use 2 adequate method contraception start screen visit , duration study participation , 120 day last dose MK3475 administration Ability understand willingness sign write informed consent document Patient prior systemic therapy MCC Note : prior systemic cytotoxic chemotherapy allow administer adjuvant setting ( clinically detectable MCC time ) treatment conclude 6 month prior begin study treatment Patient currently participate participate study investigational systemic agent treat MCC ; use investigational device within 4 week first dose treatment NOTE : patient receive major surgery , must recover adequately toxicity and/or complication intervention prior start therapy Toxicity surgery associate intervention recover = &lt; grade 1 allow meet inclusion requirement laboratory parameter Patients locoregional disease receive appropriate standard locoregional therapy surgery and/or radiation therapy Patient radiation therapy within 2 week begin study treatment Toxicity prior radiation therapy NOT resolve grade 1 less Patient diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment Patient prior monoclonal antibody treatment MCC Patient prior monoclonal antibody noncancer therapy indication within 4 week prior study day 1 recover ( i.e. , = &lt; grade 1 baseline ) adverse event ( AEs ) due agent administer 4 week earlier Patient know additional malignancy progress require active treatment ; exception include basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy Patient know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis Patients previously treat brain metastasis may participate provide stable ( without evidence progression image least 4 week prior first dose trial treatment neurologic symptom return baseline ) , evidence new enlarge brain metastasis , use steroid least 7 day prior trial treatment Patient history allergic reaction attribute compound similar chemical biologic composition MK3475 Patient active autoimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent ; patient vitiligo resolve childhood asthma/atopy would exception rule ; patient require intermittent use bronchodilator local steroid injection would exclude study ; use physiologic dos corticosteroid may approve consultation protocol principal investigator ( PI ) Cancer Immunotherapy Trials Network ( CITN ) ; patient hypothyroidism stable hormone replacement Sjorgen 's syndrome exclude study Patient history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere patient 's participation full duration trial , best interest patient participate , opinion treat investigator Patient know psychiatric substance abuse disorder would interfere cooperation requirement trial Patient uncontrolled intercurrent illness include , limited , ongoing active infection , interstitial lung disease , noninfectious pneumonitis , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Patient pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment NOTE : pregnant woman exclude study ; breastfeed discontinue mother treated MK3475 Men nonpregnant , nonbreastfeeding woman may enrol willing use 2 method birth control consider highly unlikely conceive ; highly unlikely conceive define ( 1 ) surgically sterilize , ( 2 ) postmenopausal ( woman &gt; = 45 year age menses great 1 year consider postmenopausal ) , ( 3 ) heterosexually active duration study ; 2 birth control method barrier method barrier method plus hormonal method prevent pregnancy ; subject start use birth control screen visit throughout study period 120 day last dose study therapy The following consider adequate barrier method contraception : diaphragm , condom ( partner ) , copper intrauterine device , sponge , spermicide ; appropriate hormonal contraceptive include register marketed contraceptive agent contains estrogen and/or progestational agent ( include oral , subcutaneous , intrauterine , intramuscular agent ) Patients inform take study medication may involve unknown risk fetus ( unborn baby ) pregnancy occur study ; order participate study , must adhere contraception requirement ( describe ) duration study followup period describe ; question subject reliably comply requirement contraception , subject enter study Pregnancy : patient inadvertently become pregnant treatment MK3475 , patient immediately remove study ; site contact patient least monthly document patient 's status pregnancy complete terminate ; outcome pregnancy report without delay within 24 hour outcome serious adverse experience ( e.g. , death , abortion , congenital anomaly , disable lifethreatening complication mother newborn ) ; study investigator make every effort obtain permission follow outcome pregnancy report condition fetus newborn ; male patient impregnates female partner study personnel site must inform immediately pregnancy report followed Subjects breastfeed eligible enrollment Patient human immunodeficiency virus ( HIV ) positive Note : patient human immunodeficiency virus ( HIV ) positive may participate IF meet follow eligibility requirement : They must stable antiretroviral regimen , must healthy HIV perspective They must cluster differentiation ( CD ) 4 count great 250 cells/mcL They must receive prophylactic therapy opportunistic infection Patient know active hepatitis B ( e.g. , hepatitis B surface antigen [ HBsAg ] reactive ) hepatitis C ( e.g. , hepatitis C virus [ HCV ] ribonucleic acid [ RNA ] [ qualitative ] detect ) Note : positive hepatitis B serology indicative previous immunization ( i.e. , hepatitis B surface antibody [ HBsAb ] positive hepatitis B core antibody [ HBcAb ] negative ) fully resolve acute hepatitis B infection exclusion criterion Has active noninfectious pneumonitis &gt; = grade 2 ; history grade 3 noninfectious pneumonitis within past 12 month ; history grade 4 noninfectious pneumonitis History pulmonary disease emphysema chronic obstructive pulmonary disease ( COPD ) , ( forced expiratory volume 1 second [ FEV1 ] &lt; 60 % predict height age ) ; pulmonary function test ( PFTs ) require patient prolonged smoke history symptom respiratory dysfunction Cardiovascular disease meet one following : congestive heart failure ( New York Heart Association class III IV ) , active angina pectoris , recent myocardial infarction ( within last 6 month ) Prior organ allograft allogeneic transplantation , transplant tissue still place Patient live vaccine within 30 day first dose trial treatment participate trial ; example live vaccine include , limited , follow : measles , mumps , rubella , chicken pox , yellow fever , seasonal flu , H1N1 flu , rabies , bacille de Calmette et Gu√©rin ( BCG ) , typhoid vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>